A Revolutionary Approach to Cancer Treatment

Jounce Therapeutics, Inc. (NASDAQ: JNCE) is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefit to patients. Jounce utilizes its Translational Science Platform to first focus on specific cell types within tumors to prioritize targets, and then identify related biomarkers designed to match the right therapy to the right patient.

Year Invested: 2013
Location: Cambridge, Mass.
Visit: www.jouncetx.com

Recent News

June 5, 2017
Jounce Therapeutics Presents Phase 1 Data from ICONIC Study of JTX-2011 in Patients with Advanced Solid Tumors at 2017 ASCO Annual Meeting

May 17, 2017
Jounce Therapeutics to Present Phase 1 Data from JTX-2011 ICONIC Trial at 2017 American Society of Clinical Oncology Annual Meeting

May 9, 2017
Jounce Therapeutics Reports First Quarter 2017 Financial Results

Read More News

Associated Team Members

Robert Tepper, M.D.

Cary Pfeffer, M.D.

Perry Karsen
Venture Partner

Robert Kamen, Ph.D.